Frequently Asked Questions About Alzheimer's Disease.
The Alzheimer's Disease Research Center studies the entire spectrum of aging, from normal aging to mild cognitive impairment to dementia in cooperation with the Mayo Clinic Study of Aging. The Mayo Clinic Study of Aging, one of the largest and longest running studies on aging, began in 2004 and has recruited more than 3,000 people.
Alzheimer’s disease (AD) is a neurological disease framed in the group of neurodegenerative (are those that produce degeneration of the essential cells of the nervous system, neurons). It is the disease that most frequently causes senile dementia (loss of mental faculties in the elderly).
Overview of Alzheimer’s Disease Alzheimer’s disease (AD), the most common form of dementia, is a degenerative disorder of the brain that leads to memory loss1. AD affects 5.3 million Americans and is the seventh leading cause of death in the United States. There are two main forms of the disease.
Download file to see previous pages The person who inherits genetic mutations is most likely to develop Alzheimers disease before age 65 and in worst case the person may develop Alzheimers disease as early as age 30. Genetics and advancing age contribute significantly to developing Alzheimers disease in an individual. Medications can reduce the symptoms but cannot alter the disease.
Alzheimer’s develops over time, but the speed of change varies between people. As Alzheimer’s progresses, symptoms may include: People will find that their ability to remember, think and make decisions worsens. Communication and language become more difficult. People may have difficulty recognising household objects or familiar faces.
Alzheimers Disease: The Symptoms Of Alzheimer's Disease. Alzheimer’s disease is described as a progressive brain disorder that gradually destroys a person’s memory and clarity to learn, reason, make judgments, communicate, and carry out daily life. (r.1) Alzheimer’s is a disturbing disease affecting millions of elderly people.
Alzheimer's disease research is currently being tackled from many sides. Drug companies, the U.S. government, and the Alzheimer's Association are funding research to learn more about the disease.